Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.

@article{Sandri2016VemurafenibRI,
  title={Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.},
  author={Silvana Sandri and Fernanda Fai{\~a}o-Flores and Manoela Tiago and Paula Comune Pennacchi and Renato Ramos Massaro and D{\'e}bora Kristina Alves-Fernandes and Gustavo Noriz Berardinelli and Adriane Feij{\'o} Evangelista and Vinicius de Lima Vazquez and Rui Manuel Reis and Silvya Stuchi Maria-Engler},
  journal={Pharmacological research},
  year={2016},
  volume={111},
  pages={
          523-533
        }
}

Tables from this paper

Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas.
BACKGROUND Melanoma is the most aggressive skin cancer, and BRAF (V600E) is the most frequent mutation that led to the development of BRAF inhibitors (BRAFi). However, patients treated with BRAFi
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
TLDR
It is shown that melanoma cells resistant to the BRAF inhibitor are characterized by a lower proliferation rate and they acquire a spindle-like shape, and combination therapy reduced their viability, as measured with a colorimetric cytotoxicity test, and decreased invasiveness.
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular
FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor
TLDR
It is concluded that FOXD1 might be a promising new diagnostic marker and a therapeutic target for the treatment of targeted therapy resistant melanoma.
Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
TLDR
Melanoma cells derived from different regions of the same tumor may differ by mutations status, molecular processes and biological response to target therapy, and the downregulation of semaphorin-5A may be involved in divergent effects of anticancer agents on tumor cell biology.
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
TLDR
It is reported here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis.
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies
TLDR
Recent evidence underlining the hallmarks of fibrotic diseases in drug-exposed and resistant melanoma, including increased remodeling of the extracellular matrix, enhanced actin cytoskeleton plasticity, high sensitivity to mechanical cues, and the establishment of an inflammatory microenvironment is summarized.
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
TLDR
The data suggest that intermittent inhibition of BET proteins may improve the duration of responses following BRAFi/MEKi treatment in BRAF-mutant melanoma.
...
...

References

SHOWING 1-10 OF 71 REFERENCES
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
TLDR
A targeted combinatorial strategy to overcome PLX4032/vemurafenib resistance in melanoma cell lines or short-term culture where the resistance is driven by PDGFRβ upregulation, achieving synergistic growth inhibition and cytotoxic response is defined.
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
TLDR
The findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
TLDR
It is demonstrated that vemurafenib-resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumours, and a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug- resistant cells in the absence of the drug, forestalls the onset of lethal drug- resisting disease.
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
TLDR
The data implicate reactivation of the RAS/RAF pathway by upstream signaling activation as a key mechanism of acquired resistance to vemurafenib, in support of clinical studies in which combination therapy with other targeted agents are being strategized to combat resistance.
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
TLDR
It is shown that RAF inhibitor-sensitive and inhibitor-resistant BRAF(V600)-mutant melanomas display distinct transcriptional profiles, which may modulate intrinsic sensitivity of melanomas to MAPK pathway inhibitors.
BRAF inhibition generates a host/tumor niche that mediates therapeutic escape
TLDR
It is shown melanoma cells and fibroblasts remodel their microenvironment in response to BRAF inhibition and that these adaptations allow tumor cells to evade therapy through increased PI3K/AKT survival signaling.
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
TLDR
It is suggested that chronic BRAF inhibition elevates WNT5A expression, which promotes AKT signaling through FZD7 and RYK, leading to increased growth and therapeutic resistance in BRAFi-resistant melanomas.
The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
TLDR
Two treatments are described that appear to overcome this resistance and could deliver therapeutic efficacy in drug-resistant BRAF mutant melanoma patients andhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
PTEN regulates IGF‐1R‐mediated therapy resistance in melanoma
TLDR
It is shown that hyperactivation of BRAF enhances IGF‐1R expression and the phosphatase activity of PTEN as well as heterocellular contact to stromal cells increases IGF‐ 1R expression in melanoma cells and enhances resistance to vemurafenib.
...
...